Patients with pre-existing immunity to this peptide have been scored, in addition to breast and ovarian, also in colorectal, lung and, for the first time, in prostate cancer, demonstrating that HER-2(9369) is ideal for peptide-based vaccinations in these types of cancer. Here, ERBB2 is linked to Familial prostate cancer.